Ragan Arrison, NP
Nurse Practitioner · Hot Springs, ARNPI 1518581115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$858
- Sanofi$473
- Mallinckrodt Hospital Products Inc.$457
- Takeda Pharmaceuticals U.S.A., Inc.$397
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,77999%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $1,546 |
| AstraZeneca | 69 | $1,167 |
| Boehringer Ingelheim | 40 | $858 |
| Sanofi | 23 | $473 |
| Mallinckrodt Hospital Products Inc. | 20 | $457 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $397 |
| Mylan Specialty L.p. | 18 | $236 |
| Baxter Healthcare | 9 | $209 |
| Grifols USA, LLC | 8 | $199 |
| Regeneron Healthcare Solutions, Inc. | 7 | $187 |
| Electromed, Inc. | 7 | $183 |
| United Therapeutics Corporation | 7 | $168 |
| Amgen | 6 | $122 |
| Merck | 5 | $120 |
| Genentech USA, Inc. | 5 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Insmed, Inc. | 3 | $75 |
| Actelion Pharmaceuticals US, Inc. | 2 | $55 |
| Philips North America LLC | 3 | $54 |
| Verona Pharma, Inc. | 2 | $46 |
| Boston Scientific | 2 | $46 |
| Inogen, Inc. | 3 | $28 |
| Viatris Specialty LLC | 2 | $27 |
| Liquidia Technologies, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
How this compares
$6,858 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 433 | $362,120 |
| OfevNintedanib Esylate | 22 | $282,994 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $110,400 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $105,446 |
| XolairOmalizumab | 23 | $99,451 |
| Spiriva RespimatTiotropium Bromide | 82 | $45,121 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $43,549 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $41,568 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $39,200 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $31,544 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 33 | $22,622 |
| Spiriva HandihalerTiotropium Bromide | 36 | $22,464 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 48 | $21,123 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $16,900 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 112 | $15,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,546 | $467,317649 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $858 | $392,306216 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,167 | $158,113295 claims |
| Grifols USA, LLCProlastin C | $199 | $110,40012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Hot Springs
- Tiffany McConathyHot Springs$54K
- Virginia LaliberteHot Springs$21K
- Samantha WidemanHot Springs$14K
- Cody WilliamsHot Springs$12K
- Nan MeansHot Springs$7K
- Laci PattonHot Springs$7K
- Samantha BollanHot Springs$7K
- Kayla HarringtonHot Springs$6K
- Mindy FarmerHot Springs$5K
- Kristyl WoolseyHot Springs$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.